Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware,[2] and Morges, Switzerland.[3]
The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991[4] and Incyte Genomics, Inc. of Delaware.[5] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[6]
Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
^"Incyte Corp. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 13 February 2022.
^"INCY". www.nasdaq.com. Retrieved 2021-07-26.
^"Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
^Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
^"Certificate of Ownership and Merger". www.sec.gov. Retrieved 2021-07-26.
^"Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company...
Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in...
treatment of Merkel cell carcinoma. The applicant for this medicinal product is Incyte Biosciences Distribution B.V. Retifanlimab is the international nonproprietary...
Retrieved 3 June 2013. "Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo". Incyte. 19 July 2022. Archived...
on the filing is expected in August 2020. In January 2020, MorphoSys and Incyte Corporation signed a collaboration and license agreement for the global...
"Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)". Incyte. 21...
being investigated by Incyte and Merck & Co. in several cancers, as was the combination of epacadostat with nivolumab (Opdivo) by Incyte and Bristol Myers...
eliminated via the urine, and 20% via the faeces. Baricitinib was discovered by Incyte and licensed to Eli Lilly. In January 2016, Eli Lilly submitted a new drug...
(ruxolitinib) Tablets, for Oral Use. Full Prescribing Information" (PDF). Incyte Corporation. Archived (PDF) from the original on 2 April 2016. Retrieved...
619–625. PMID 21224796. "FDA Approves Incyte's Jakafi (ruxolitinib) for Patients with Myelofibrosis" (Press release). Incyte. Archived from the original on 24...
of Pemazyre to Incyte Corporation. On 24 August 2018, orphan designation (EU/3/18/2066) was granted by the European Commission to Incyte Biosciences Distribution...
1159/000441250. PMID 26735937. S2CID 207742214. "FDA Approves Lilly and Incyte's Olumiant (baricitinib) As First and Only Systemic Medicine for Adults with...
Supplies & Components Illumina ILMN Health Care Life Sciences Tools & Services Incyte INCY Health Care Biotechnology Informatica INFA Information Technology Ingersoll...
tumor necrosis factor of cancer cells. Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development...
of property is planned to be sold to the pharmaceutical research company Incyte. Ashley Biden, American social worker, activist, philanthropist, and fashion...
"Nike Total 90 Tracer". FOOT-BALLZ.COM. Retrieved 15 February 2024. "Nike Incyte is official match ball of Gold Cup 2013 | Football Balls Database". football-balls...
Global Information
US$3.69 billion (2023)